bioAffinity Technologies, Inc. (BIAF)
| Market Cap | 3.42M |
| Revenue (ttm) | 7.68M |
| Net Income (ttm) | -11.69M |
| Shares Out | 976.19K |
| EPS (ttm) | -20.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 301,849 |
| Open | 4.160 |
| Previous Close | 4.290 |
| Day's Range | 3.455 - 4.160 |
| 52-Week Range | 3.455 - 67.776 |
| Beta | 2.54 |
| Analysts | Hold |
| Price Target | n/a |
| Earnings Date | Nov 13, 2025 |
About BIAF
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have... [Read more]
Financial Performance
In 2024, bioAffinity Technologies's revenue was $9.36 million, an increase of 269.68% compared to the previous year's $2.53 million. Losses were -$9.04 million, 13.9% more than in 2023.
Financial StatementsNews
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today announced it will effect a 1-for-30 reverse split of its common stock at the opening of trading on September 19, 2025.
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--CyPath® Lung identifies incidentally found ground-glass lung nodules, leading to early diagnosis and timely treatment.
bioAffinity Technologies Appoints New Members to Board of Directors
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies appoints leaders in corporate finance and the diagnosis and treatment of asthma and COPD to its Board of Directors.
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies closes private placement and warrant inducement transaction for approximately $1.2 million in gross proceeds.
bioAffinity Technologies Reports Second Quarter 2025 Results
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports Q2 2025 results; CyPath Lung revenues up 62% year-over-year in first six months of 2025.
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of private placement and warrant inducement transaction.
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports a significant surge in commercial sales of CyPath® Lung with back-to-back record monthly sales in June and July.
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--CyPath® Lung detects a rare mucinous adenocarcinoma at Stage 1A in a high-risk individual whose previous tests suggested a low probability of cancer.
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Canada grants bioAffinity Technologies new patent that protects its proprietary technology that powers its flagship product, CyPath® Lung.
bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies has received notification of allowance from China for a patent on its technology for predicting the likelihood of lung cancer.
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity scientists present breakthrough research on using siRNAs to knock down two receptors on the cell membrane to selectively kill cancer cells.
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--China has issued a notification of patent grant to bioAffinity for its novel method of using siRNAs to selectively kill cancer cells.
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board
SAN ANTONIO--(BUSINESS WIRE)-- #ALA--bioAffinity CEO Maria Zannes joins the American Lung Association in Texas' Leadership Board of to advance prevention and treatment of lung disease.
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces new patent for method of selectively killing cancer by targeting two specific receptors on the cell membrane.
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Pulmonologist Gordon Downie, MD, PhD, joins bioAffinity Technologies as Chief Medical Officer.
bioAffinity Technologies Reports First Quarter 2025 Results
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies reports first-quarter 2025 results.
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--A newly released white paper shares four real-world cases where bioAffinity's CyPath® Lung played a pivotal role in guiding clinical decisions.
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
JERSEY CITY, N.J. , May 7, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc....
bioAffinity Technologies Announces Closing of $3.25 Million Offering
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies today closed the previously announced best efforts offering of securities for aggregate gross proceeds of $3.25 million.
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering
JERSEY CITY, N.J. , May 6, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc....
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces the pricing of a best efforts offering of securities for aggregate gross proceeds of $3.25 million.
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies is implementing efficiency measures for CyPath Lung that streamline lab processing and data acquisition and reduce lab costs.
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (BIAF) releases financial results for 2024.
Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies' CyPath Lung test uncovered a hidden second primary lung cancer in a patient who had been treated for lung cancer earlier.
Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--In another case study, CyPath® Lung helped physicians identify and treat a recurrence of breast cancer in a high-risk patient.